Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

September 12, 2022
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN, Texas , Sept. 12, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its
September 6, 2022
Natera to Participate in Upcoming Investor Conferences
AUSTIN, Texas , Sept. 6, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman , chief executive officer, and Mike Brophy , chief financial officer, will be presenting at the following upcoming investor conferences:    
August 25, 2022
Natera Earns Great Place to Work Certification™ for Second Consecutive Year
AUSTIN, Texas , Aug. 25, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at
August 11, 2022
Natera Announces Enrollment Completion for RenaCARE Study
RenaCARE Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease AUSTIN, Texas , Aug. 11, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight
August 10, 2022
Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT
AUSTIN, Texas , Aug. 10, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama®

Upcoming Events

More events are coming soon.

Past events